Navigation Links
Using nanotechnology, UCLA researchers discover cancer cells 'feel' much softer than normal cells
Date:12/2/2007

A multidisciplinary team of UCLA scientists were able to differentiate metastatic cancer cells from normal cells in patient samples using leading-edge nanotechnology that measures the softness of the cells.

The study, published Dec. 2, 2007 in the advance online edition of the journal Nature Nanotechnology, represents one of the first times researchers have been able to take living cells from cancer patients and apply nanotechnology to analyze them and determine which were cancerous and which were not. The nano science measurements may provide a potential new method for detecting cancer, especially in cells from body cavity fluids where diagnosis using current methods is typically very challenging. The method also may aid in personalizing treatments for patients.

When cancer is becoming metastatic, or invading other organs, the diseased cells must travel throughout the body. Because the cells need to enter the bloodstream and maneuver through tight anatomical spaces, cancer cells are much more flexible, or softer, than normal cells. These spreading, invading cancer cells can cause a build-up of fluids in body cavities such as the chest and abdomen. But fluid build-up in patients does not always mean cancer cells are present. If the fluid could be quickly and accurately tested for the presence of cancer, oncologists could make better decisions about how aggressive a treatment should be administered or if any treatment is necessary at all.

In this study, researchers collected fluid from the chest cavities of patients with lung, breast and pancreatic cancers, a relatively non-invasive procedure. One problem with diagnosing metastatic disease in this setting is that cancer cells and normal cells in body cavity fluids look very similar under an optical microscope, said Jianyu Rao, a researcher at UCLAs Jonsson Cancer Center, an associate professor of pathology and laboratory medicine and one of the studys senior authors. Conventional di
'/>"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
2. Fever causing headaches for Aussie parents
3. Using evolution, UW team creates a template for many new therapeutic agents
4. Using green chemistry to deliver cutting-edge drugs
5. IGERT fellows to design biodevices using flexible electronics
6. Prediction of RNA pseudoknots using heuristic modeling with mapping and sequential folding
7. Computer program traces ancestry using anonymous DNA samples
8. Using nanotubes to detect and repair cracks in aircraft wings, other structures
9. Book on weeds and invasive plants discusses how to manage them using ecological approaches
10. Study shows housing development on the rise near national forests
11. Rare cancer-causing syndrome found, for the first time, in Singapore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Evidence exists that cannabinoid receptor type 1 ... Ca2+ influx, and reduce neurotransmitter release. However, ... 1 can increase extracellular Ca2+ influx and ... his team, Tongji Hospital Affiliated to Tongji ... Technology, China used whole cell voltage-clamp and ...
(Date:7/11/2014)... Janeiro, Brazil- In the brains of all vertebrates, ... allows an electric or chemical signal to be ... synapses, which are the most abundant type of ... formation is crucial for learning, memory, perception and ... synapses critical for brain function. For instance, ...
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... This news release is available in ... November 26, 2013 In the developing world, Cryptosporidium ... decade ago, it announced its presence in the United States, ... the county,s history. Its rapid ability to spread, combined with ...
... new study reveals how pollution causes thunderstorms to leave ... Proceedings of the National Academy of Sciences ... reveal how pollution plays into climate warming. The work ... weather and climate models. Researchers had thought that ...
... mild cognitive impairment is a transitional stage between ... networks during this transformation have yet to be ... University of Technology, China constructed brain networks using ... four populations (normal controls, patients with early mild ...
Cached Biology News:Treatment target identified for a public health risk parasite 2The lingering clouds 2The lingering clouds 3
(Date:7/11/2014)... , Not for release, publication or distribution (in whole ... to do so would constitute a violation of the relevant ... the "Company") (LSE: SHP, NASDAQ: SHPG ) notes ... a meeting with representatives of AbbVie. This statement ... approval of AbbVie. A further update will be ...
(Date:7/11/2014)... 11, 2014  Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/10/2014)... Understanding the need for better quality ... the gap that currently exists in this area, ChanTest ... portfolio of validated ion channel and GPCR cell lines. ... as ion channels control many critical physiological functions throughout ... the potential to treat a variety of human diseases. ...
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... BEIJING , June 1 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems ... and,sale of medical products in China , said today that it ... anesthesia product manufactured,by Penlon, a UK firm specializing in anesthesia and breathing ... , ...
... -- Pioneer Surgical Technology, Inc. is pleased to announce that the ... study patients was presented at the recent 10th annual meeting of The ... Orleans by Domagoj Coric , M.D., Chief, Department of Neurosurgery, ... , ...
... June 1 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... has received approval from the Belgian Federal Agency for ... 3 trial examining REOLYSIN in combination with paclitaxel and ... This is the same trial that was agreed to ...
Cached Biology Technology:Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 2Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 3Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 4Two-Year Follow up Data of NuBac® IDE Feasibility Study Was Presented at SAS Meeting 2Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4
... GenePix Pro is the industry standard ... unique combination of imaging and analysis tools, ... use. GenePix Pro is included with every ... images from third-party scanners and all types ...
... the one mouse-click image analysis software ... It is the solution for high ... images. MicroVigene is empowered with VigeneTechs ... grid, regional 2D-curve fitting background correction ...
... For applications not requiring confocal, the ... alternative to the Pathway 435. And, the ... if later applications require it. ... can elect to use the laser autofocus, ...
... Proteomic Imaging System, Professional Package Superior ... Dynamic Range: The ProXPRESS 2D Proteomic Imaging ... system for both proteomic and general life ... flexibility, enabling the use of all dyes ...
Biology Products: